Tags

Type your tag names separated by a space and hit enter

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
J Clin Psychiatry. 2011 Jul; 72(7):955-61.JC

Abstract

OBJECTIVE

To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder.

METHOD

We used the data acquired in the European First-Episode Schizophrenia Trial, an open, randomized trial (conducted in 14 countries) comparing 5 antipsychotic drugs in 498 patients aged 18-40 years with first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. DSM-IV diagnostic criteria were used. Patients were assessed between December 23, 2002 and January 14, 2006. Most subjects joined the study as inpatients and then continued with follow-ups in outpatient clinic visits. The Positive and Negative Syndrome Scale (PANSS) was administered at baseline and at 1, 3, 6, 9, and 12 months after randomization. We analyzed the scores on the PANSS hostility item in a subset of 302 patients showing at least minimal hostility (a score > 1) at baseline. We hypothesized (1) that the treatments would differ in their efficacy for hostility and (2) that olanzapine would be superior to haloperidol. Our primary statistical analysis tested the null hypothesis of no difference among the treatment groups in change in hostility over time. Secondary analysis addressed the question of whether the effects on hostility found in the primary analysis were specific to this item. All our analyses were post hoc.

RESULTS

The primary analysis of hostility indicated an effect of differences between treatments (F(4,889) = 4.02, P = .0031). Post hoc treatment-group contrasts for hostility change showed that, at months 1 and 3, olanzapine was significantly superior (P < .05) to haloperidol, quetiapine, and amisulpride in reducing hostility. Secondary analyses demonstrated that these results were at least partly specific to hostility.

CONCLUSIONS

Both hypotheses were supported. Olanzapine appears to be a superior treatment for hostility in early phases of therapy for first-episode schizophrenia, schizoaffective disorder, and schizophreniform disorder. This efficacy advantage of olanzapine must be weighed against its adverse metabolic effects and propensity to cause weight gain.

TRIAL REGISTRATION

ISRCTN Register Identifier: ISRCTN68736636.

Authors+Show Affiliations

Department of Psychiatry, New York University School of Medicine, New York, NY, USA. janvolavka@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21824456

Citation

Volavka, Jan, et al. "Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)." The Journal of Clinical Psychiatry, vol. 72, no. 7, 2011, pp. 955-61.
Volavka J, Czobor P, Derks EM, et al. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2011;72(7):955-61.
Volavka, J., Czobor, P., Derks, E. M., Bitter, I., Libiger, J., Kahn, R. S., & Fleischhacker, W. W. (2011). Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). The Journal of Clinical Psychiatry, 72(7), 955-61. https://doi.org/10.4088/JCP.10m06529
Volavka J, et al. Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2011;72(7):955-61. PubMed PMID: 21824456.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). AU - Volavka,Jan, AU - Czobor,Pal, AU - Derks,Eske M, AU - Bitter,Istvan, AU - Libiger,Jan, AU - Kahn,René S, AU - Fleischhacker,W Wolfgang, AU - ,, PY - 2010/08/26/received PY - 2010/11/15/accepted PY - 2011/8/10/entrez PY - 2011/8/10/pubmed PY - 2011/10/1/medline SP - 955 EP - 61 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 72 IS - 7 N2 - OBJECTIVE: To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. METHOD: We used the data acquired in the European First-Episode Schizophrenia Trial, an open, randomized trial (conducted in 14 countries) comparing 5 antipsychotic drugs in 498 patients aged 18-40 years with first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder. DSM-IV diagnostic criteria were used. Patients were assessed between December 23, 2002 and January 14, 2006. Most subjects joined the study as inpatients and then continued with follow-ups in outpatient clinic visits. The Positive and Negative Syndrome Scale (PANSS) was administered at baseline and at 1, 3, 6, 9, and 12 months after randomization. We analyzed the scores on the PANSS hostility item in a subset of 302 patients showing at least minimal hostility (a score > 1) at baseline. We hypothesized (1) that the treatments would differ in their efficacy for hostility and (2) that olanzapine would be superior to haloperidol. Our primary statistical analysis tested the null hypothesis of no difference among the treatment groups in change in hostility over time. Secondary analysis addressed the question of whether the effects on hostility found in the primary analysis were specific to this item. All our analyses were post hoc. RESULTS: The primary analysis of hostility indicated an effect of differences between treatments (F(4,889) = 4.02, P = .0031). Post hoc treatment-group contrasts for hostility change showed that, at months 1 and 3, olanzapine was significantly superior (P < .05) to haloperidol, quetiapine, and amisulpride in reducing hostility. Secondary analyses demonstrated that these results were at least partly specific to hostility. CONCLUSIONS: Both hypotheses were supported. Olanzapine appears to be a superior treatment for hostility in early phases of therapy for first-episode schizophrenia, schizoaffective disorder, and schizophreniform disorder. This efficacy advantage of olanzapine must be weighed against its adverse metabolic effects and propensity to cause weight gain. TRIAL REGISTRATION: ISRCTN Register Identifier: ISRCTN68736636. SN - 1555-2101 UR - https://www.unboundmedicine.com/medline/citation/21824456/Efficacy_of_antipsychotic_drugs_against_hostility_in_the_European_First_Episode_Schizophrenia_Trial__EUFEST__ L2 - http://www.psychiatrist.com/jcp/article/pages/2011/v72n07/v72n0711.aspx DB - PRIME DP - Unbound Medicine ER -